Medrx Co (4586.T) Stock Price

Medrx Co Price

CLOSED
59.00
​
Market closed

Revenue at Medrx Co has contracted by 4.2% per year over the past 18 years to 128.08 M JPY. For Medrx Co, the net margin of -731.8% is up versus -12,692.6% a few years ago.

Medrx Co stock price

Access this data via the Eulerpool API

Medrx Co business model & stock analysis

Medrx Co. Ltd. engages in the business of pharmaceutical drug development based on the transdermal absorption. The company is headquartered in Higashikagawa-Shi, Kagawa-Ken and currently employs 22 full-time employees. The company went IPO on 2013-02-13. The firm produces new medicines based on percutaneous absorption formulation technology. The firm has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.

Frequently asked questions about Medrx Co

Converted at the current exchange rate, the Medrx Co share trades at 0.33 EUR (59.00 JPY).

The revenue cannot currently be calculated for Medrx Co.

The profit cannot currently be calculated for Medrx Co.

The P/E ratio cannot be calculated for Medrx Co at the moment.

The P/S cannot be calculated for Medrx Co currently.

The Eulerpool Quality Score for Medrx Co is 4/10.

The ISIN of Medrx Co is JP3921220004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Medrx Co is 4586.T. The ticker symbol is used to trade Medrx Co shares on the stock exchange.

Fair ValueTerminal
59.00 JPY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
5.82 M JPY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website medrx.co.jp
Country
Currency
JPY
Initial public offering
Feb 13, 2013
ISIN
JP3921220004
Cusip
J41574104
Market capitalization
3.50 B JPYMid Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2026
—
P/Se
—
EV/EBIT
—
P/B Ratio
1.71
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-45.75 %
Gross Margin
88.23 %
EBIT Margin
-735.45 %
Net Margin
-731.84 %
EPS (Earnings Per Share)
-14.52 JPY
Net Debt / EBIT
—
Debt/Equity
0.00
Last updated Oct 5, 2026, 2:57 PM

Medrx Co Peer Group

Medrx Co FIGI

4586:JP · BBG003S4JL614586:JT · BBG003T0NXY64586:JJ · BBG003T0NY744586:JE · BBG003T0NYB94586:JI · BBG003T0NYC84586:JU · BBG003T0NYD74586:JW · BBG00875LDH34586:JV · BBG0193RCVW9

All fundamentals and in-depth analysis of Medrx Co

Our stock analysis for Medrx Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medrx Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.